Champions Oncology, Inc. (CSBR) Stock Price & Analysis
Champions Oncology, Inc. (CSBR) rose 2.17% to USD 6.13 as of July 25, 2026 at 05:23 UTC, according to Nexqual real-time market data.
CSBR last closed at USD 6; the session ranged USD 5.75–6.16 on volume of 11,059 shares. Market capitalization is $85.13M, with a 52-week range of USD 5.5–8.74 (NCM). Source: Nexqual, July 25, 2026 at 05:23 UTC.
Key Statistics (as of July 25, 2026 at 05:23 UTC)
| Price | USD 6.13 |
|---|---|
| Change | ▲ 2.17% (up) |
| Previous Close | USD 6 |
| Open | USD 6.06 |
| Day Range | USD 5.75 – 6.16 |
| 52-Week Range | USD 5.5 – 8.74 |
| Volume | 11,059 shares |
| Market Cap | $85.13M |
| Exchange | NCM |
Technical Analysis (CSBR)
Nexqual's technical model rates CSBR "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 05:23 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 55.85 (neutral) |
| vs SMA50 | Above (USD 6.04) |
| MACD | -0 (negative) |
Analyst Ratings (CSBR)
Wall Street analysts rate CSBR "None", per Nexqual as of July 25, 2026 at 05:23 UTC.
| Consensus Rating | None |
|---|
Earnings (CSBR)
| Next Earnings Date | 2026-07-27 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-10-31 | USD 0.06 vs est 0 ▲ beat |
| 2025-07-31 | USD 0.02 vs est -0.01 ▲ beat |
| 2025-04-30 | USD -0.12 vs est -0.2 ▲ beat |
| 2025-01-31 | USD 0.33 vs est -0.01 ▲ beat |
Source: Nexqual, July 25, 2026 at 05:23 UTC.
Financials & Fundamentals (CSBR)
| Total Revenue | $57.95M |
|---|---|
| Revenue Growth (YoY) | -2.80% |
| Gross Margin | +45.88% |
| Operating Margin | -1.13% |
| Profit Margin | -4.04% |
| ROE | -47.59% |
| Debt / Equity | 114.19 |
| Current Ratio | 0.98 |
| Total Cash | $7.13M |
| Total Debt | $5.00M |
| Free Cash Flow | $4.70M |
Source: Nexqual, July 25, 2026 at 05:23 UTC.
Financial Health Score (CSBR)
Nexqual rates Champions Oncology, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 05:23 UTC.
| Growth | Solid — Revenue +14% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 46%, operating -1% |
| Balance Sheet | Weak — $7M cash vs $5M debt, net cash position |
| Cash Flow | Solid — FCF $5M, 8% margin |
| Efficiency | Critical — ROE -48%, ROA -4.7% |
Ownership (CSBR)
| Insider Ownership | +26.67% |
|---|---|
| Institutional Ownership | +41.35% |
| Shares Outstanding | 13.89M |
| Float | 6.07M |
| Short % of Float | +1.11% |
Source: Nexqual, July 25, 2026 at 05:23 UTC.
Leadership (CSBR)
Champions Oncology, Inc. is led by Robert Brainin (age 54), CEO & Director, per Nexqual as of July 25, 2026 at 05:23 UTC.
| CEO & Director | Robert Brainin (age 54) |
|---|---|
| Chief Financial Officer | David Barry Miller (age 56) |
| Chief Operating Officer | Maria Mancini |
| Executive Vice President of Growth, Strategy & Enablement | Marianna Zipeto |
Major Backers & Investors (CSBR)
Notable institutional backers of Champions Oncology, Inc. include Battery Management Corp., NEA Management Company, LLC, Tocqueville Asset Management L.p., according to Nexqual as of July 25, 2026 at 05:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Battery Management Corp. | 17.44% |
| NEA Management Company, LLC | 12.34% |
| Tocqueville Asset Management L.p. | 2.3% |
| Morgan Stanley | 1.74% |
| Renaissance Technologies | 1.05% |
| Mink Brook Asset Management LLC | 0.8% |
| Fidelity | 0.47% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.32% |
| BlackRock | 1.05% |
| Geode Capital | 0.56% |
Source: Nexqual, July 25, 2026 at 05:23 UTC.
From Champions Oncology, Inc.'s Latest SEC 10-K Filing (filed 2025-07-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Software As A Service (SaaS) Business Our SaaS business is centered around our proprietary software platform and data tool, Lumin Bioinformatics ("Lumin"), which contains comprehensive information derived from our research services and clinical studies and is sold to customers on an annual subscription basis.
- The Datacenter combines our proprietary dataset with other large publicly available datasets.
- Drug Discovery and Developmen t: Our Drug Discovery and Development business places us in a good position of also competing against the same customers of our Research Services and/or SaaS businesses: the global biopharmaceutical industry.
- At the core of our research platforms is our unique, proprietary bank of Patient Derived Xenograft (PDX) models.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ICCC | ImmuCell Corporation | USD 11.03 | ▼ 0.9% |
| FENC | Fennec Pharmaceuticals Inc. | USD 9.99 | ▼ 3.2% |
| CPIX | Cumberland Pharmaceuticals Inc. | USD 6.61 | ▼ 7.16% |
| CBIO | Crescent Biopharma, Inc. | USD 16.3 | ▲ 2.97% |
| ATXI | Avenue Therapeutics, Inc. | USD 0.28 | ▲ 2.22% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:23 UTC. This page is informational and not investment advice.